CAMBRIDGE, Mass., Aug. 31 /PRNewswire/ -- Genzyme Corporation today
welcomed publication of "The Cure," a new book by Geeta Anand that reveals
for the general public the enormous challenges faced by patients and
families struggling with Pompe disease, a very rare and potentially fatal
inherited disorder. In addition, the book portrays the extraordinary
commitment of scientists, physicians, patient associations and companies
involved in Pompe research.
Ms. Anand's narrative also highlights the risks, setbacks and
difficulty of the drug development process and underscores the perseverance
and massive investment required to bring a drug toward approval.
"The Cure" profiles John Crowley, the father of two children with Pompe
disease, who became increasingly involved in the Pompe research community
in the late 1990s, in an effort to enroll his children in a clinical trial.
John subsequently served as chief executive of Novazyme Pharmaceuticals,
and following Genzyme's acquisition of Novazyme, led the company's Pompe
program from September 2001-December 2002.
"The remarkable energy and determination shown by John and his wife
Aileen to help their children reflects the courage and commitment displayed
by all parents of children with Pompe and other rare diseases," said Edward
Kaye, M.D., vice president of clinical research for Genzyme. "We hope this
book will raise awareness of Pompe disease, and we are excited that the
general public will get a glimpse of the unheralded people and institutions
throughout the Pompe community who have worked for many years in the
difficult quest to develop a treatment for this disease."
For more information about Pompe disease, please visit
http://www.genzyme.com.
About Genzyme
One of the world's leading biotechnology companies, Genzyme is
dedicated to making a major positive impact on the lives of people with
serious diseases. This year marks the 25th anniversary of Genzyme's
founding. Since 1981, the company has grown from a small start-up to a
diversified enterprise with more than 8,500 employees in locations spanning
the globe and 2005 revenues of $2.7 billion. Genzyme has been selected by
FORTUNE as one of the "100 Best Companies to Work for" in the United
States.
With many established products and services helping patients in more
than 80 countries, Genzyme is a leader in the effort to develop and apply
the most advanced technologies in the life sciences. The company's products
and services are focused on rare inherited disorders, kidney disease,
orthopaedics, cancer, transplant and immune diseases, and diagnostic
testing. Genzyme's commitment to innovation continues today with a
substantial development program focused on these fields, as well as heart
disease and other areas of unmet medical need.
SOURCE Genzyme Corporation
 back to top
Related links:
http://www.genzyme.com
http://www.prnewswire.com/comp/104284.html /
CONTACT:
Bo Piela of Genzyme Corporation,
+1-617-768-6579
|
